Assembly Biosciences, Inc. Debt Securities, Available-for-sale, Amortized Cost, Current
Assembly Biosciences, Inc. (ASMB) had Debt Securities, Available-for-sale, Amortized Cost, Current of $288.43 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2026-08-13
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost, Current $288.43M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost, Current $195.58M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $189.42M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost, Current $209.84M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2026-06-30 | $288.43M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $195.58M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $189.42M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $209.84M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $50.98M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $67.59M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $73.67M 10-K · filed 2026-03-19 |
| 2024-09-30 | $66.39M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $90.03M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $94.19M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $110.21M 10-K · filed 2025-03-20 |
| 2023-09-30 | $19.56M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $38.26M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $29.77M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $39.72M 10-K · filed 2024-03-28 |
| 2022-09-30 | $54.70M 10-Q · filed 2022-11-08 |
| 2021-12-31 | $101.04M 10-K · filed 2023-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |